Dylan Dupuis
Stock Analyst at Roth MKM
(2.65)
# 2,058
Out of 4,876 analysts
9
Total ratings
44.44%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.17 | +498.29% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $3.05 | +260.66% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $3.83 | +500.52% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $26.52 | +20.66% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $0.77 | +1,196.34% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.17
Upside: +498.29%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $3.05
Upside: +260.66%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $3.83
Upside: +500.52%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $26.52
Upside: +20.66%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $0.77
Upside: +1,196.34%